GlaxoSmithKline has spent 20 years trying to develop an improved vaccine for tuberculosis, and new data for its lead candidate M72/AS01E suggests it is getting closer to a breakthrough in the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback